Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) Fell 5.72% Intraday, Turnover at HKD 22.6718 Million
NewTimeSpace News: As of 15:21 on July 16, Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) dropped 5.72%, with the latest price at HKD 10.550. The ETF opened at HKD 11.000, reached a high of HKD 11.180 and a low of HKD 10.370, with an intraday amplitude of 7.24%. It traded 2.0816 Million shares with a turnover of HKD 22.6718 Million and an average price of HKD 10.892. The latest Net Asset Value (NAV) stands at HKD 11.248. Assets Under Management (AUM) at HKD 163 Million, with 14.5 Million total shares issued and a board lot size of 100 shares.
Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) tracks the ChiNext Index. Launched by the Shenzhen Stock Exchange in 2010, the index is a constituent benchmark comprising the 100 most representative stocks with the largest market capitalization and highest liquidity in the ChiNext market. The index focuses on strategic emerging industries and high-tech enterprises, with significant coverage of high-growth sectors such as New Energy (e.g., power battery leaders), Biopharmaceuticals, Information Technology, and Advanced Manufacturing.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- GHPC (01847.HK): Appoints Wang Junjie as Chief Engineer, Term Expiring Upon Completion of the Third Board of Directors
- INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline
- HENLIUS (02696.HK): Biosimilar HLX18 to Nivolumab Doses First Patient in China for Global Multi-centre Phase I Trial
- BIDU-SW (09888.HK): Proposes Voluntary Conversion to Dual Primary Listing on HKEX Main Board
- CSOP FTSE China A50 ETF (02822.HK) Fell 2.25% Intraday, AUM at HKD 7.318 Billion